A5075269446- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- Genomic variations and chromosomal abnormalities
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Monoclonal and Polyclonal Antibodies Research
- Computational Drug Discovery Methods
- DNA Repair Mechanisms
- Virus-based gene therapy research
- Chemotherapy-induced cardiotoxicity and mitigation
- Pharmacogenetics and Drug Metabolism
- CAR-T cell therapy research
- Cancer Research and Treatments
- Inflammatory mediators and NSAID effects
- PI3K/AKT/mTOR signaling in cancer
- PARP inhibition in cancer therapy
Amgen (Canada)
2025
Hospital Universitario De Cabueñes
2025
GEICAM – Spanish Breast Cancer Group
2016-2024
Consorcio Hospitalario Provincial de Castellón
2008-2024
Fundación Neumológica Colombiana
2024
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2019-2023
Fundación Hospital Provincial de Castellón
2013-2023
Hospital Clínic de Barcelona
2018-2022
Solti
2021
Centre Léon Bérard
2021
The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this detects most mutations in BC. This information critical as clinicians using other genomic assays indicate alpelisib.Data from 6338 BC was explored across 10 publicly available studies. primary objective evaluate proportion distribution of...
Abstract Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 paired primary tissues from patients. Intrinsic subtype was identified using a PAM50 classifier χ2 tests determined the differences variable distribution. The rate conversion 0% basal-like tumors, 23.1% HER2-enriched (HER2-E) 30.0% luminal B 55.3% A tumors. 40.2% cases, tumors converted...
The prognostic and predictive value of intrinsic subtypes in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with endocrine therapy ribociclib (RIB) is currently unknown. We evaluated the association progression-free survival (PFS) MONALEESA trials.A retrospective exploratory PAM50-based analysis tumor samples from phase III MONALEESA-2, MONALEESA-3, MONALEESA-7 trials was undertaken. relationship PFS risk disease progression by...
Both clinical and genomic data independently predict survival treatment response in early-stage HER2-positive breast cancer. Here we present the development validation of a new HER2DX risk score, pathological complete (pCR) both based on 27-gene expression plus feature-based classifier.HER2DX is supervised learning algorithm incorporating tumour size, nodal staging, 4 gene signatures tracking immune infiltration, cell proliferation, luminal differentiation, HER2 amplicon, into single score....
Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion chemotherapy in patients early TNBC.Eligible were those operable, node-positive-or node negative tumor 1 cm or greater-TNBC, prior anthracycline- and/or taxane-containing chemotherapy. After central confirmation TNBC status by immunohistochemistry, randomly assigned to either...
To assess palbociclib in combination with trastuzumab or without endocrine therapy patients HER2-positive advanced breast cancer.PATRICIA is a prospective, open-label, multicenter phase II trial. Patients had received 2-4 prior lines of anti-HER2-based regimens. Treatment consisted 200 mg daily for 2 weeks and 1 week off plus trastuzumab. The study was based on Simon two-stage design comprising three cohorts: estrogen receptor (ER)-negative (cohort A), ER-positive B1), letrozole B2). were...
The HER2-enriched (HER2-E) subtype within HER2-positive (HER2+) breast cancer is highly addicted to the HER2 pathway. However, ∼20-60% of HER2+/HER2-E tumors do not achieve a complete response following anti-HER2 therapies. Here we evaluate gene expression data before, during and after neoadjuvant treatment with lapatinib trastuzumab in PAMELA trial cell lines. Our results reveal that dual blockade HER2-E disease induces low-proliferative Luminal A phenotype both patient's vitro models....
Mechanisms driving tumor progression from less aggressive subtypes to more states represent key targets for therapy. We identified a subset of luminal A primary breast tumors that give rise HER2-enriched (HER2E) subtype metastases, but remain clinically HER2 negative (cHER2–). By testing the unique genetic and transcriptomic features these cases, we developed hypothesis FGFR4 likely participates in this switching. To evaluate this, 2 genomic signatures using patient-derived xenograft (PDX)...
Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism trastuzumab orchestrates epithelial-to-mesenchymal transition and heterodimerizes with HER2, leading to activation PI3K/AKT MAPK pathways ligand-independent manner. Genetic depletion pharmacological inhibition restored response vitro vivo. inhibitor plus achieved complete...
Abstract Liquid biopsy has proven valuable in identifying individual genetic alterations; however, the ability of plasma ctDNA to capture complex tumor phenotypes with clinical value is unknown. To address this question, we have performed 0.5X shallow whole-genome sequencing from 459 patients metastatic breast cancer, including 245 treated endocrine therapy and a CDK4/6 inhibitor (ET + CDK4/6i) 2 independent cohorts. We demonstrate that machine learning multi-gene signatures, obtained ctDNA,...
Abstract Despite their recognised role in HER2-positive (HER2+) breast cancer (BC), the composition, localisation and functional orientation of immune cells within tumour microenvironment, as well its dynamics during anti-HER2 treatment, is largely unknown. We here investigate changes tumour-immune contexture, assessed by stromal tumour-infiltrating lymphocytes (sTILs) multiplexed spatial cellular phenotyping, treatment with lapatinib-trastuzumab HER2+ BC patients (PAMELA trial). Moreover,...
Abstract Purpose: It is not clear that the published estimates of breast and ovarian cancer penetrances mutations in BRCA1 BRCA2 can be used genetic counseling countries such as Spain, where incidence general population considerably lower, prevalence seems to higher, a distinct spectrum recurrent exists for both genes. We aimed estimate these women attending units Spain. Experimental Design: collected phenotype genotype data on 155 164 mutation carrier families from 12 centers across...
Capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 adjuvant trial to investigate the integration of capecitabine into a regimen epirubicin and docetaxel for node-positive early BC.Patients with operable BC (T1-3/N1-3) were eligible. After surgery, 1,384 patients randomly assigned receive plus cyclophosphamide (EC; 90 600 mg/m(2), respectively, × four cycles), followed by (100 mg/m(2) cycles; EC-T) or (ET; 75 (1,250 twice day on days 1 14, ET-X); all regimens...
The objective of this study was to determine the conversion rate human epidermal growth factor receptor 2 (HER2), estrogen (ER) and progesterone (PR) between primary tumors metastatic lesions in advanced breast cancer. Patients with suspected diagnosis locally recurrent or cancer, either at first relapse after successive disease progressions, who had an appropriately preserved sample from a tumor were scheduled for biopsy lesion, included. Blinded determinations status on paired samples...
BackgroundCYP2D6 is a key enzyme in tamoxifen metabolism, transforming it into its main active metabolite, endoxifen. Poor CYP2D6 metabolizers (PM) have lower endoxifen plasma concentrations and possibly benefit less from treatment with tamoxifen. We evaluated dose adjustment PM patients order to obtain of comparable extensive metabolism (EM).Patients methodsComprehensive genotyping metabolite were performed among 249 breast cancer adjuvant Tamoxifen was increased 40 mg 60 daily for 4-month...
Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that heterogeneity in response seen partly explained by levels gene (ERBB2) mRNA. We analyzed ERBB2 expression using a clinically applicable assay formalin-fixed paraffin-embedded (FFPE) tumors (primary or metastatic) from...
In advanced breast cancer, biomarker identification and patient selection using a metastatic tumor biopsy is becoming more necessary. However, the biology of metastasis according to organ site largely unknown. Here, we evaluated expression 771 genes in 184 samples across 11 organs, including liver, lung, brain, bone, made following observations. First, all PAM50 molecular intrinsic subtypes were represented organs within immunohistochemistry-based groups. Second, HER2-low disease was...
Abstract Background The prognostic and predictive value of the two nonluminal (human epidermal growth factor receptor 2 [HER2]-enriched basal-like) subtypes within advanced hormone receptor-positive (HR+) breast cancer is currently unknown. Materials Methods This study retrospectively analyzed 261 tumors (80.7% primary; 19.3% metastatic) from BOLERO-2 study; randomized 724 patients with HR+/HER2-negative to everolimus plus exemestane or placebo exemestane. Tumors were classified using a...
•ADCs and CAR-T therapies target TSAs.•We propose a novel bioinformatic-based methodology to identify BC subtype-specific TSA for ADC CAR-T.•As proof of concept we identified 36 potentially suitable targets predicted their toxicity profile.•We also 63 potential pairs that might be appropriate co-targeting.•The was relatively easy reproduce, less time- resource-consuming based on publicly available databases. BackgroundTwo promising therapeutic strategies in oncology are chimeric antigen...
Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin prevent or reduce hyperglycaemia occurrence in patients with HR+/HER2-/
Abstract Background ABP-501 (AMGEVITA®), biosimilar to adalimumab reference product (RP), was approved by Health Canada in 2021 for use different immune diseases, including inflammatory bowel disease (IBD), comprising Crohn’s (CD) and ulcerative colitis (UC). Aims To assess the real-world use, effectiveness satisfaction of naïve switch patients with IBD across Canada. Methods Data were drawn from Adelphi Disease Specific ProgrammeTM, a cross-sectional survey retrospective data collection...
Background/Objectives: Bence Jones proteins (BJPs) are monoclonal immunoglobulin free light chains (FLCs) that appear in the urine of patients with plasma cell disorders, including multiple myeloma (MM), Waldenström’s macroglobulinemia (WM), or chain amyloidosis (AL). Their presence can provide valuable information about disease progression and treatment efficacy. These typically detected through a 24-h collection, as recommended by clinical guidelines. However, this method be inconvenient...